[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-t-cell-lymphoblastic-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-t-cell-lymphoblastic-leukemia":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100545431",false,"NCT06381817","Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Patients with acute T cell lymphoblastic leukemia\n* With available minimal residual disease parameters assessed by flow cytometry and\u002For quantitative polymerase chain reaction\n* Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* With other malignancies\n* Failing to acquire a suitable unrelated cord blood unit\n* With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy\n* With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation\n* With severe organ dysfunction\n* In pregnancy or lactation period\n* With any conditions not suitable for the trial (investigators' decision)","ALL",{"count":17,"type":18},146,"ESTIMATED","INTERVENTIONAL",[21],"PHASE3","The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:\n\nDose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.\n\nParticipants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.",[24,25,26],"Acute T Cell Lymphoblastic Leukemia","Haploidentical Hematopoietic Stem Cell Transplantation","Cord Blood","RECRUITING","2024-04-24",{"date":30,"type":31},"2024-04-26","ACTUAL",{"date":33,"type":31},"2024-04-01",{"date":35,"type":18},"2028-03-31",{"name":37,"class":38},"The First Affiliated Hospital of Soochow University","OTHER",""]